Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Nancy Raitano, McQuaid Goldie A, Jiddou Haila, McNulty Jessica, Grosman Hannah E, Tucker Kamaria T, O'Brien Meghan, Wallace Gregory L
Аннотация
INTRODUCTION: Anticholinergic (AC) medication use is considered a risk factor for cognitive impairment and deterioration in the general population; yet, this has not been examined in Down syndrome (DS), a disorder with high dementia rates.
METHODS: Family members of 108 young adults with DS (18-39 years) reported on their loved one's medication use, executive function, and changes in cognition and behavior using a dementia screener. Medications were coded for their AC potency using the CRIDECO Anticholinergic Load Scale (CALS).
RESULTS: Forty percent of the sample was taking at least one medication with a CALS AC potency of ≥1. These individuals were reported to have greater executive function difficulties and more changes in cognition/behavior relative to those not taking AC medications.
DISCUSSION: AC medication use may represent a modifiable risk factor for cognitive deterioration in adults with DS; more research on this topic, particularly with older adults with DS, is needed.
HIGHLIGHTS: Identifying modifiable risk factors for dementia in Down syndrome (DS) is critical. A risk factor studied in the general population is anticholinergic (AC) medication. This risk factor has not been studied in DS, a high-risk group. AC medication use was associated with everyday cognitive challenges in young adults with DS. Longitudinal studies across adulthood, including older adults with DS, are needed.
METHODS: Family members of 108 young adults with DS (18-39 years) reported on their loved one's medication use, executive function, and changes in cognition and behavior using a dementia screener. Medications were coded for their AC potency using the CRIDECO Anticholinergic Load Scale (CALS).
RESULTS: Forty percent of the sample was taking at least one medication with a CALS AC potency of ≥1. These individuals were reported to have greater executive function difficulties and more changes in cognition/behavior relative to those not taking AC medications.
DISCUSSION: AC medication use may represent a modifiable risk factor for cognitive deterioration in adults with DS; more research on this topic, particularly with older adults with DS, is needed.
HIGHLIGHTS: Identifying modifiable risk factors for dementia in Down syndrome (DS) is critical. A risk factor studied in the general population is anticholinergic (AC) medication. This risk factor has not been studied in DS, a high-risk group. AC medication use was associated with everyday cognitive challenges in young adults with DS. Longitudinal studies across adulthood, including older adults with DS, are needed.